Welcome to our dedicated page for Tenon Medical news (Ticker: TNON), a resource for investors and traders seeking the latest updates and insights on Tenon Medical stock.
Tenon Medical, Inc. reports developments as a medical device company focused on minimally invasive solutions for sacro-pelvic and sacroiliac joint disorders. Company news centers on the Catamaran System and the SImmetry® and SImmetry®+ SI Joint Fusion Systems, including product clearances, initial clinical use, commercial rollout activity, and intellectual property covering SI joint implant technologies.
Recurring updates also include quarterly and annual financial results, revenue trends from SI joint product sales, capital raises through private placements and convertible notes, and funding uses tied to commercial expansion, product development, clinical studies, working capital, and general corporate purposes.
Tenon Medical (NASDAQ:TNON), a company focused on treating sacroiliac joint disorders, has announced the timing of its second quarter 2024 financial results. The company will release its financial results for the quarter ended June 30, 2024, after market close on Tuesday, August 13, 2024. This will be followed by a conference call at 4:30 p.m. Eastern Time on the same day to discuss the results in detail and conduct a Q&A session with covering analysts. Investors can join the call via phone or webcast, with dial-in numbers provided for both domestic and international participants. An audio replay will be available until August 27, 2024, through Tenon's Investor Relations website or via telephone.
Tenon Medical (NASDAQ:TNON) reported significant growth in its Q1 2024 financial results, showcasing a 66% year-over-year revenue increase to $719,000, driven by a 42% rise in Catamaran System surgical procedures.
The company achieved a gross profit of $470,000, marking a stark improvement from a gross loss of ($47,000) in Q1 2023, with a stable gross margin of 65%.
Notable developments include positive fusion results from a post-market study of the Catamaran SI Joint Fusion System and the receipt of a U.S. patent allowance for its Catamaran implant.
The company reduced its operating losses to $3.5 million, down from $4.9 million in Q1 2023, and ended the quarter with $4.4 million in cash and cash equivalents.
Additionally, Tenon retired $1.25 million in debt through a $2.6 million Series A Preferred Stock financing.
Tenon Medical, Inc. will announce its first quarter 2024 financial results on May 14, 2024, after market close. The company will host a conference call to discuss the results in detail, followed by a Q&A session with analysts. Investors can access the call via dial-in or webcast and listen to the playback on the Investor Relations website.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.